ACTINEX
LOE Approachingmasoprocol
NDATOPICALCREAM
Approved
Sep 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTINEX (masoprocol) is a topical cream indicated for actinic keratosis, a precancerous skin condition caused by sun exposure. The mechanism of action involves antioxidant and anti-inflammatory properties that help prevent progression of damaged skin lesions. It is applied directly to affected skin areas.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting declining revenue trajectory and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect a mature, stable-to-declining product with minimal hiring momentum. Career opportunities would focus on maintaining market share and managing the transition to genericization rather than growth.
Brand ManagerSales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.